{
    "nct_id": "NCT03706365",
    "official_title": "A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer",
    "inclusion_criteria": "* Histologically confirmed adenocarcinoma of the prostate.\n* Metastatic prostate cancer documented by positive bone scan and/or measurable soft tissue metastatic lesions by CT or magnetic resonance imaging (MRI).\n* Progressive disease at study entry demonstrated during continuous androgen-deprivation therapy (ADT)/post orchiectomy defined as one or more of the following:\n\n  * PSA progression\n  * Radiographic progression per Response Evaluation Criteria in Solid Tumors (RECIST)1.1 for soft tissue and/or per Prostate Cancer Working Group 3 (PCWG3) for bone, with or without PSA progression\n* Have adequate organ function.\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior therapy with cytochrome P450 (CYP)17 inhibitors.\n* Prior treatment with abemaciclib or any cyclin-dependent kinase (CDK) 4 & 6 inhibitors.\n* Prior cytotoxic chemotherapy for metastatic castration resistant prostate cancer (participants treated with docetaxel in the metastatic hormone-sensitive prostate cancer [mHSPC] are eligible). Prior radiopharmaceuticals for prostate cancer, or prior enzalutamide, apalutamide, darolutamide or sipuleucel-T. Participants who had prior radiation or surgery to all target lesions.\n* Currently enrolled in a clinical study involving an investigational product.\n* Gastrointestinal disorder affecting the absorption or ability to swallow large pills.\n* Clinically significant heart disease, active or chronic liver disease, moderate/severe hepatic impairment (Child-Pugh Class B and C).",
    "miscellaneous_criteria": ""
}